Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. (February 2019)

• Record Type: Journal Article
• Authors: Parola, Maurizio; Pinzani, Massimo
• Is Part Of: Molecular aspects of medicine. Volume 65(2019)
• Page Start: 37
• Page End: 55
• Publication Date: 2019-02
• Subjects: Hepatic myofibroblasts -- Hepatic stellate cells -- Liver fibrosis -- Liver biopsy -- Transient elestography; Pathology, Molecular -- Periodicals; Medicine -- Periodicals; Biochemistry -- Periodicals; Medicine -- Periodicals; Molecular Biology -- Periodicals; Pathologie moléculaire -- Périodiques; Médecine -- Périodiques; Electronic journals; 612.015
• DOI: 10.1016/j.mam.2018.09.002
• Languages: English
• ISSNs: 0098-2997

Abstract

Abstract: The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic parenchymal injury, persistent activation of inflammatory response as well as sustained activation of liver fibrogenesis and wound healing response. Liver fibrogenesis, is a dynamic, highly integrated molecular, cellular and tissue process responsible for driving the excess accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) sustained by an eterogeneous population of hepatic myofibroblasts (MFs). The process of liver fibrogenesis recognizes a number of common and etiology-independent mechanisms and events but it is also significantly influenced by the specific etiology, as also reflected by peculiar morphological patterns of liver fibrosis development. In this review we will analyze the most relevant established and/or emerging pathophysiological issues underlying CLD progression with a focus on the role of critical hepatic cell populations, mechanisms and signaling pathways involved, as they represent potential therapeutic targets, to finally analyze selected and relevant clinical issues.